Thelansis

APOL1-Mediated Kidney Disease (AMKD) Market Outlook Thelansis’s “APOL1-Mediated Kidney Disease (AMKD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential APOL1-Mediated Kidney Disease (AMKD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

  APOL1-Mediated Kidney Disease (AMKD) Market Outlook Thelansis’s “APOL1-Mediated Kidney Disease (AMKD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential APOL1-Mediated Kidney Disease (AMKD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). APOL1-Mediated Kidney Disease (AMKD) Overview Apolipoprotein L-1 (APOL1) variants pose a heightened risk of end-stage kidney disease (ESRD) among African American individuals. These coding variants are associated explicitly with non-diabetic chronic kidney disease, focal segmental glomerulosclerosis (FSGS), and HIV-associated nephropathy in patients of African descent. APOL1, a small 42 kd prote...

  Apolipoprotein L-1 (APOL1) variants pose a heightened risk of end-stage kidney disease (ESRD) among African American individuals. These coding variants are associated explicitly with non-diabetic chronic kidney disease, focal segmental glomerulosclerosis (FSGS), and HIV-associated nephropathy in patients of African descent. APOL1, a small 42 kd protein primarily found in the kidney and enriched in glomeruli, harbors two allelic variants: G1 (S342G and I384M) and G2 (N388del: Y389del), both altering the APOL1 protein sequence within an anti-trypanosome activity domain. The majority of individuals with recent African ancestry diagnosed with HIV-associated nephropathy (HIVAN), FSGS, and hypertension-attributed ESRD exhibit APOL1-associated kidney disease. Clinical studies on kidney transplantation reveal no significant correlation between APOL1 genotype and serum APOL1 protein levels or kidney disease presence. The persistent disparities in long-term outcomes following kidney tran...